These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21626328)

  • 1. Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients.
    Yang H; Lin M; Xiong F; Yang Y; Nie X; McNutt MA; Zhou R
    Surg Today; 2011 Jun; 41(6):810-7. PubMed ID: 21626328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
    Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAPTM4B-35 is a novel prognostic factor of hepatocellular carcinoma.
    Yang H; Xiong F; Qi R; Liu Z; Lin M; Rui J; Su J; Zhou R
    J Surg Oncol; 2010 Apr; 101(5):363-9. PubMed ID: 20358632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
    Meng F; Tan S; Liu T; Song H; Lou G
    Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma.
    Yang H; Zhai G; Ji X; Xiong F; Su J; McNutt MA
    PLoS One; 2012; 7(4):e34984. PubMed ID: 22509374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo.
    Yang H; Xiong F; Wei X; Yang Y; McNutt MA; Zhou R
    Cancer Lett; 2010 Aug; 294(2):236-44. PubMed ID: 20202745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LAPTM4B-35, a cancer-related gene, is associated with poor prognosis in TNM stages I-III gastric cancer patients.
    Cheng X; Zheng Z; Bu Z; Wu X; Zhang L; Xing X; Wang X; Hu Y; Du H; Li L; Li S; Zhou R; Wen XZ; Ji JF
    PLoS One; 2015; 10(4):e0121559. PubMed ID: 25849595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study.
    Meng F; Luo C; Hu Y; Yin M; Lin M; Lou G; Zhou R
    Int J Gynecol Pathol; 2010 Nov; 29(6):587-93. PubMed ID: 20881850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LAPTM4B allele *2 is a marker of poor prognosis for gallbladder carcinoma.
    Zhai G; Yan K; Ji X; Xu W; Yang J; Xiong F; Su J; McNutt MA; Yang H
    PLoS One; 2012; 7(9):e45290. PubMed ID: 22984631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
    Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LAPTM4B-35 overexpression is an independent prognostic marker in endometrial carcinoma.
    Meng FL; Yin MZ; Song HT; Yang H; Lou G; Zhou RL
    Int J Gynecol Cancer; 2010 Jul; 20(5):745-50. PubMed ID: 20966643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysosomal-associated protein transmembrane 4 Beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma.
    Liu L; Xu X; Jing L; Zhou G; Cao Z; Han Y; Zhou R
    PLoS One; 2015; 10(2):e0118026. PubMed ID: 25689860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.
    Peng C; Zhou RL; Shao GZ; Rui JA; Wang SB; Lin M; Zhang S; Gao ZF
    World J Gastroenterol; 2005 May; 11(18):2704-8. PubMed ID: 15884107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
    Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
    Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LAPTM4B overexpression is an independent prognostic marker in ovarian carcinoma.
    Yang Y; Yang H; McNutt MA; Xiong F; Nie X; Li L; Zhou R
    Oncol Rep; 2008 Nov; 20(5):1077-83. PubMed ID: 18949404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced expression of argininosuccinate lyase is closely associated with postresectional survival in hepatocellular carcinoma: an immunohistochemistry study of 61 cases.
    Yang H; Zhai G; Ji X; Su J; Lin M
    Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):602-6. PubMed ID: 22531684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression signature of lysosomal-associated transmembrane protein 4B in hepatitis C virus-induced hepatocellular carcinoma.
    Roy G; Roy P; Bhattacharjee A; Shahid M; Misbah M; Gupta S; Husain M
    Int J Biol Markers; 2018 Aug; 33(3):283-292. PubMed ID: 29882487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
    Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma.
    Wu L; Li L; Meng S; Qi R; Mao Z; Lin M
    J Gastroenterol Hepatol; 2013 Feb; 28(2):365-8. PubMed ID: 23339388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.